Details

Autor(en) / Beteiligte

• Brasher, Nicholas A.
• Eltahla, Auda A.
• Underwood, Alexander
• Boo, Irene
• Rizzetto, Simone
• Walker, Melanie R.
• Rodrigo, Chaturaka
• Luciani, Fabio
• Maher, Lisa
• Drummer, Heidi E.
• Tedla, Nicodemus
• Lloyd, Andrew R.
• Bull, Rowena A.

Titel

B cell immunodominance in primary hepatitis C virus infection

Ist Teil von

• Journal of hepatology, 2020-04, Vol.72 (4), p.670-679

Ort / Verlag

Netherlands: Elsevier B.V

Erscheinungsjahr

2020

Link zum Volltext

Quelle

Elsevier ScienceDirect Journals Complete

Beschreibungen/Notizen

• Neutralising antibodies (NAbs) play a key role in clearance of HCV. NAbs have been isolated and mapped to several domains on the HCV envelope proteins. However, the immunodominance of these epitopes in HCV infection remains unknown, hindering efforts to elicit optimal epitope-specific responses. Furthermore, it remains unclear which epitope-specific responses are associated with broad NAb (bNAb) activity in primary HCV infection. The aim of this study was to define B cell immunodominance in primary HCV, and its implications on neutralisation breadth and clearance. Using samples from 168 patients with primary HCV infection, the antibody responses targeted 2 immunodominant domains, termed domains B and C. Genotype 1 and 3 infections were associated with responses targeted towards different bNAb domains. No epitopes were uniquely targeted by clearers compared to those who developed chronic infection. Samples with bNAb activity were enriched for multi-specific responses directed towards the epitopes antigenic region 3, antigenic region 4, and domain D, and did not target non-neutralising domains. This study outlines for the first time a clear NAb immunodominance profile in primary HCV infection, and indicates that it is influenced by the infecting virus. It also highlights the need for a vaccination strategy to induce multi-specific responses that do not target non-neutralising domains. Neutralising antibodies will likely form a key component of a protective hepatitis C virus vaccine. In this work we characterise the predominant neutralising and non-neutralising antibody (epitope) targets in acute hepatitis C virus infection. We have defined the natural hierarchy of epitope immunodominance, and demonstrated that viral genotype can impact on this hierarchy. Our findings highlight key epitopes that are associated with broadly neutralising antibodies, and the deleterious impact of mounting a response towards some of these domains on neutralising breadth. These findings should guide future efforts to design immunogens aimed at generating neutralising antibodies with a vaccine candidate. [Display omitted] •Neutralising antibodies will likely form a key component of an HCV vaccine.•We characterise the immunodominance of neutralising and non-neutralising epitopes in primary HCV infection.•We identify that virus genotype might influence the epitopes targeted.•We also identify that certain epitope target combinations are associated with greater breadth.